Home › Funds › General Catalyst Group Management, LLC › MAZE

General Catalyst Group Management, LLC position in MAZE

MAZE THERAPEUTICS INC · Health Care

General Catalyst Group Management, LLC reported holding 1,035,910 shares of MAZE (MAZE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$30.9M, representing 16.40% of its reported portfolio and ranking #4 among its reported holdings. General Catalyst Group Management, LLC has disclosed MAZE holdings in 6 of the last 6 reported quarters, going back to Q1 2025.

Latest position (Q2 2026)1.04M sh
Reported value held$30.91M
Portfolio Weight16.40%
First reportedQ1 2025
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How General Catalyst Group Management, LLC's MAZE position evolved

General Catalyst Group Management, LLC first disclosed a stake in MAZE in Q1 2025 at 1,035,910 shares (US$11.4M). The position peaked in Q4 2025 at 1,035,910 shares, worth US$42.9M. Across 6 filings, General Catalyst Group Management, LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 1,035,910 shares valued at US$30.9M.

Quarter by quarter

QuarterSharesValueChange
Q1 2025 1.04M $11.41M New
Q2 2025 1.04M $12.71M Hold
Q3 2025 1.04M $26.86M Hold
Q4 2025 1.04M $42.92M Hold
Q1 2026 1.04M $30.92M Hold
Q2 2026 1.04M $30.91M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MAZE and 13F data

MAZE (MAZE THERAPEUTICS INC) is a Health Care company. 74 other funds we track also report a position in MAZE — the largest reported positions include Frazier Life Sciences Management, L.P. (US$150.2M), TRV GP IV, LLC (US$133.5M), ARCH Venture Management, LLC (US$123.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MAZE

All MAZE fund holders →

FAQ

How long has General Catalyst Group Management, LLC held MAZE?

General Catalyst Group Management, LLC has disclosed MAZE holdings in 6 of the last 6 reported quarters, going back to Q1 2025.

What is General Catalyst Group Management, LLC's current position in MAZE?

As of Q2 2026, General Catalyst Group Management, LLC holds 1.04M shares of MAZE (MAZE THERAPEUTICS INC), valued at $30.91M, representing 16.40% of its reported portfolio and ranking #4.

Has General Catalyst Group Management, LLC been buying or selling MAZE?

In the latest 13F filing (Q2 2026), General Catalyst Group Management, LLC held unchanged its position in MAZE. The position peaked in Q4 2025 at 1.04M shares.

Which other funds hold MAZE?

Other major institutional holders of MAZE include Frazier Life Sciences Management, L.P., TRV GP IV, LLC, ARCH Venture Management, LLC, among 74 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.